Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The recombinant C1 esterase inhibitor is a glyco-optimized protein developed by CSL Limited and CEVEC using CEVEC's proprietary CAP(R)Go technology platform. This drug is designed to improve the half-life and provide a more convenient application for patients. Its primary mechanism involves replacing or supplementing the activity of endogenous C1 esterase inhibitor, thereby regulating the complement and contact systems. It is being developed for the treatment of Hereditary Angioedema (HAE) and other potential indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant C1 esterase inhibitor.